NBT Bank N A NY reduced its position in shares of Merck & Co. (NYSE:MRK) by 0.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 84,786 shares of the company’s stock after selling 273 shares during the period. NBT Bank N A NY’s holdings in Merck & Co. were worth $4,885,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Americafirst Capital Management LLC bought a new position in Merck & Co. during the second quarter worth approximately $115,000. NewSquare Capital LLC boosted its position in Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock worth $121,000 after buying an additional 261 shares during the period. First New York Securities LLC NY bought a new position in Merck & Co. during the second quarter worth approximately $121,000. Lowe fs LLC boosted its position in Merck & Co. by 1.8% in the second quarter. Lowe fs LLC now owns 2,619 shares of the company’s stock worth $151,000 after buying an additional 46 shares during the period. Finally, JNBA Financial Advisors boosted its position in Merck & Co. by 3.1% in the second quarter. JNBA Financial Advisors now owns 3,012 shares of the company’s stock worth $174,000 after buying an additional 91 shares during the period. 72.94% of the stock is owned by institutional investors.

Shares of Merck & Co. (NYSE:MRK) traded down 1.53% during trading on Monday, hitting $61.33. The company had a trading volume of 11,255,844 shares. The firm has a market capitalization of $169.59 billion, a P/E ratio of 33.64 and a beta of 0.63. The company’s 50 day moving average is $61.95 and its 200 day moving average is $57.17. Merck & Co. has a 1-year low of $47.97 and a 1-year high of $64.00.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings results on Friday, July 29th. The company reported $0.93 EPS for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.02. The business had revenue of $9.84 billion for the quarter, compared to analysts’ expectations of $9.79 billion. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 EPS. Analysts anticipate that Merck & Co. will post $3.75 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be paid a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a yield of 3.00%. Merck & Co.’s dividend payout ratio (DPR) is currently 101.10%.

A number of research firms have recently commented on MRK. Argus reissued a “buy” rating and issued a $65.00 target price on shares of Merck & Co. in a report on Wednesday, September 14th. Morgan Stanley set a $60.00 target price on shares of Merck & Co. and gave the stock a “hold” rating in a report on Tuesday, September 13th. Jefferies Group reissued a “hold” rating and issued a $56.00 target price (down previously from $57.00) on shares of Merck & Co. in a report on Monday, September 12th. Berenberg Bank reissued a “hold” rating and issued a $62.00 target price on shares of Merck & Co. in a report on Sunday, September 11th. Finally, Barclays PLC increased their target price on shares of Merck & Co. from $66.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, September 9th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of €63.31 ($70.34).

In other Merck & Co. news, EVP Clark Golestani sold 3,000 shares of Merck & Co. stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Adam H. Schechter sold 50,000 shares of Merck & Co. stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of €57.69 ($64.10), for a total value of €2,884,500.00 ($3,205,000.00). Following the completion of the transaction, the executive vice president now directly owns 50,000 shares in the company, valued at €2,884,500 ($3,205,000). The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.

Merck & Co. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.